Evaluation of a direct ELISA HIV-1/HIV-2 EIA using synthetic peptides: detect-HIV (version 2). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Evaluation of a direct ELISA HIV-1/HIV-2 EIA using synthetic peptides: detect-HIV (version 2).

Abstr Gen Meet Am Soc Microbiol. 1994;94:554 (abstract no. C-362). Unique Identifier : AIDSLINE ASM94/94313103
Chalifour RJ; Ha NH; Barbeau S; Lacroix M; BioChem ImmunoSystems Inc., Montreal, Que., Canada.

Abstract: A direct ELISA version of BioChem ImmunoSystems' synthetic peptide EIA was evaluated to establish if detecting all immunoglobulin classes improves the sensitivity of this test. HRP conjugates of 3 peptides from HIV-1 GP120, HIV-1 GP41 and HIV-2 GP36 were used to detect antibodies captured by these peptides on microtiter plates. Pending confirmatory testing, the specificity of this EIA was 99.5% (1974 fresh samples tested) while the sensitivity was 100% for HIV-1 (50/50) and 100% for HIV-2 (15/15). By testing serially diluted samples the sensitivity of the direct EIA was found to surpass that of the indirect EIA (version 1) with seroconversion samples and was of similar sensitivity with samples from later stages of HIV infection. The signal of both the direct and indirect EIAs was reduced by > 90% after IgG absorption by Protein G except with seroconversion samples where only a 30% signal reduction occurred with the direct EIA. This indicated that the improved sensitivity of the direct EIA with samples taken during seroconversion is because the direct EIA format detects IgG as well as other immunoglobulin classes.
Keywords: Enzyme-Linked Immunosorbent Assay/*METHODS Human HIV Antibodies/BLOOD HIV Envelope Protein gp120/*ANALYSIS HIV Envelope Protein gp41/*ANALYSIS HIV Seropositivity/*DIAGNOSIS HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF IgG/BLOOD Peptides/CHEMICAL SYNTHESIS Sensitivity and Specificity Viral Envelope Proteins/*ANALYSIS ABSTRACTKWDenzyme-linkedimmunosorbentassay/KWDmethodshumanhivantibodies/bloodhivenvelopeproteingp120/KWDanalysishivenvelopeproteingp41/KWDanalysishivseropositivity/KWDdiagnosishiv-1/KWDisolation&purifhiv-2/KWDisolation&purifigg/bloodpeptides/chemicalsynthesissensitivityandspecificityviralenvelopeproteins/KWDanalysisabstract
941030
M94A0851

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .